Holen Sie sich die Stockscreener-App
9.10
7.44%
0.63
Handel nachbörslich:
9.27
0.17
+1.87%
Schlusskurs vom Vortag:
$8.47
Offen:
$9
24-Stunden-Volumen:
925.92K
Relative Volume:
3.41
Marktkapitalisierung:
$609.49M
Einnahmen:
$555.06M
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-15.17
EPS:
-0.6
Netto-Cashflow:
$29.05M
1W Leistung:
+2.71%
1M Leistung:
+10.84%
6M Leistung:
+26.56%
1J Leistung:
-10.70%
1-Tages-Spanne:
$8.75
$9.53
1-Wochen-Bereich:
$8.31
$9.53
52-Wochen-Spanne:
$5.81
$11.25
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
9.10 | 567.29M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
111.04 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
370.50 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.01 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.99 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.89 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | Barrington Research | Outperform |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Bioventus Q4 Earnings Call Highlights - MarketBeat
Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Org - GuruFocus
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Bioventus (BVS) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com India
Bioventus (NASDAQ:BVS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Bioventus shares jump 7.6% on fourth-quarter earnings beat By Investing.com - Investing.com South Africa
Bioventus: Q4 Earnings Snapshot - KVUE
Bioventus 10-K: $568.1M Revenue, $0.33 Diluted EPS - TradingView
Bioventus (BVS) Exceeds Q4 Revenue Expectations, Eyes Future Gro - GuruFocus
Bioventus Q4 and Full Year 2025 Financial Results - TradingView
BIOVENTUS ($BVS) Releases Q4 2025 Earnings - Quiver Quantitative
Bioventus beats Q4 estimates, guides 2026 revenue in line By Investing.com - Investing.com India
Bioventus (NYSE:BVS) Updates FY 2026 Earnings Guidance - MarketBeat
Bioventus beats Q4 estimates, guides 2026 revenue in line - Investing.com
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Bioventus Q4 Earnings Assessment - Benzinga
Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions - TradingView
Bioventus Earnings Report: Q4 Overview - Benzinga
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Preview: Bioventus's Earnings - Benzinga
Bioventus Inc. $BVS Shares Bought by Royce & Associates LP - MarketBeat
Bioventus (BVS) versus Its Peers Critical Comparison - Defense World
Bioventus (NYSE:BVS) Stock Price Down 0.1%Should You Sell? - MarketBeat
Bioventus Inc. (BVS) Stock Analysis: Unpacking A 63.66% Potential Upside - DirectorsTalk Interviews
Reviewing Bioventus (BVS) and Its Peers - Defense World
BVS | Bioventus Inc. Class A FinancialsIncome Statement - Quiver Quantitative
Bioventus Inc. to Report Fourth Quarter Fiscal Year 2025 Financial Results on March 5, 2026 - Quiver Quantitative
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026 - GlobeNewswire
Bioventus sets March 5 call, Q4 2025 earnings and business update - Stock Titan
BVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bioventus (BVS) versus The Competition Head to Head Comparison - Defense World
Can Bioventus Inc. generate free cash flow2025 Technical Patterns & Risk Adjusted Buy/Sell Alerts - mfd.ru
Bioventus Inc. (BVS) Investor Outlook: A 69% Potential Upside And Strong Analyst Ratings - DirectorsTalk Interviews
What is Bioventus Inc.’s valuation compared to sector2025 Bull vs Bear & Daily Growth Stock Tips - mfd.ru
Critical Analysis: Bioventus (BVS) versus The Competition - Defense World
Comparing Bioventus (BVS) & Its Peers - Defense World
Bioventus (BVS) vs. Its Rivals Head to Head Review - Defense World
Bioventus (BVS) SVP gets 4,375 shares, withholds 2,133 for tax - Stock Titan
Reviewing Bioventus (BVS) and The Competition - Defense World
Understanding Momentum Shifts in (BVS) - Stock Traders Daily
Bioventus (BVS) vs. Its Rivals Head to Head Survey - Defense World
Bioventus (BVS) & Its Peers Head-To-Head Survey - Defense World
Barrington Research Initiates Coverage of Bioventus (BVS) with Outperform Recommendation - Nasdaq
Bioventus (BVS) vs. Its Rivals Financial Analysis - Defense World
Risks Report: Is Bioventus Inc. a top pick in the sectorEntry Point & Daily Risk Controlled Trade Plans - mfd.ru
Will Bioventus Inc. stock outperform Nasdaq indexNew Guidance & Fast Exit Strategy with Risk Control - mfd.ru
Will Bioventus Inc. stock maintain growth storyTrade Analysis Summary & High Yield Stock Recommendations - mfd.ru
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):